High dose of resmetirom rapidly reduces hepatic fat, fibrosis, biomarkers in NASH

High dose of resmetirom rapidly reduces hepatic fat, fibrosis, biomarkers in NASH

Resmetirom rapidly reduced hepatic fat, fibrosis and biomarkers among patients with nonalcoholic steatohepatitis, according to a presentation at the International Liver Congress.“Consistent with data that has been generated already, we see with a higher dose of 100 mg in open label cohort a drug that is safe, appears to well tolerated with some drops in noninvasive tests that are consistent with overall improvement in liver cell and liver health,” Stephen Harrison, MD, medical director, Pinnacle Clinical Research, University of, Texas, visiting professor of hepatology at theRead More

Share on facebook
Share on twitter
Share on linkedin